NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors in KalVista Pharmaceuticals, Inc. (“KalVista” or the “Company”) (NASDAQ: KALV). Those investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, extension 7980.

The investigation concerns whether KalVista the Runway and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On October 4, 2022, KalVista issued a press release announc[ing] that it completed the Phase 2 KOMPLETE clinical trial for KVD824 in the prevention of attacks in people with hereditary angioedema (HAE).” KalVista stated that “[t]his decision was based on observation of liver enzyme elevations (ALT/AST) in multiple patients across all treatment groups in the study.” KalVista’s share price fell sharply during intraday trading on October 4, 2022, on the news.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of victims of securities fraud, fiduciary breaches and corporate wrongdoing. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomlaw.com.

CONTACT:
Robert S Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980